Stay updated with breaking news from Pascal Touchon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reaffirmed their neutral rating on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q2 2024 earnings at $0.06 EPS, Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings […]
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Free Report) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Atara Biotherapeutics in a research note issued on Wednesday, May 22nd. HC Wainwright analyst R. Burns expects that the biotechnology company will post earnings of ($0.27) per share for the quarter. […]
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) CEO Pascal Touchon sold 81,506 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $0.62, for a total transaction of $50,533.72. Following the completion of the sale, the chief executive officer now owns 1,829,146 shares […]
First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and...